An Introduction to Airway Disease
The incidence of respiratory allergies is increasing, particularly in industrialized areas. Allergic inflammation can occur in both the upper and lower airways, and can differ substantially in intensity. Traditional drug therapy such as antihistamines, corticosteroids, anticholinergic agents and leukotriene inhibitors is important in reducing and preventing symptoms and is essential in acute use. More recent therapies including anti-immunoglobin E (IgE) therapy, anti-interleukin (IL) monoclonal antibodies, and phosphodiesterase 4/phospholipaseA2 inhibitors, have improved outcomes. However, in order to develop more effective therapies, further research is needed into the molecular mechanisms underlying respiratory allergy onset, particularly in terms of intracellular reactions and the cytosolic Ca2+ balance.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Airway Diseases Content
Pulmonary Alveolar Proteinosis: An Overview and Emerging Therapeutics
touchREVIEWS in Respiratory & Pulmonary Diseases. 2023;8(1):21–27 DOI: https://doi.org/10.17925/USRPD.2023.8.1.21
Pulmonary alveolar proteinosis (PAP) is a rare pulmonary syndrome with a prevalence of approximately seven cases per 1 million individuals.1,2 PAP affects people of all age, sex, race and socioeconomic status. Based on the largest population studies conducted in the United States and Japan, the median age for diagnosis in Japan is 51 years with a male:female […]
Lisa Sarfaty: Exploring and addressing inequities in rare diseases
Rare diseases can present numerous challenges for those living with these conditions and the healthcare professionals caring for them. In this interview we discuss some of these with Lisa Sarfaty, VP of Communication and Engagement for NORD (The National Organization for Rare Disorders) and explore ways in which they could be tackled. Questions Could you […]
Lisa Sarfaty: Help support Rare Disease Day
Our society partner, NORD (The National Organization for Rare Disorder) has planned several initiatives to support this year’s Rare Disease Day on 28 February. These activities are aimed at raising awareness about rare diseases and the challenges faced by people living with these conditions. In this video, Lisa Sarfaty, NORD’s VP of Communication and Engagement, […]
Management of severe paediatric asthma: From hospital to home
Members of the MDT and a patient advocate discuss the optimal management of severe asthma in children
- Recall the diagnostic workup for severe type 2 asthma in children
- Explain the pathophysiology of severe type 2 asthma and how this can guide treatment decisions
- Discuss the importance of the MDT in optimizing the management of children with severe asthma
Management of patients with NTM-LD: Improving adherence for optimal outcomes
Watch expert pulmonologists discuss how to optimize the diagnosis and management of patients with NTM-LD
- Appraise strategies to reduce time to diagnosis for patients with NTM-LD
- Utilize guideline recommendations when setting individualized treatment goals for patients with NTM-LD
- Apply strategies to manage adverse events for improved outcomes and adherence in patients with NTM-LD
Minimizing the clinical burden of chronic rhinosinusitis with nasal polyposis
Watch ENT specialists discuss key considerations in optimizing the management of patients with CRSwNP.
- Describe the burden of disease of CRSwNP and the importance of early diagnosis
- Explain the pathophysiology of CRSwNP and how this can guide treatment decisions
- Summarize the clinical evidence supporting the use of current and emerging treatment options for CRSwNP
Strategies for the management of severe type 2 asthma: Expert insight into optimizing care
MDT specialists, plus a patient with severe asthma, discuss the disease burden and the role of biologics in the long-term management of severe T2 asthma
- Recognize the challenges associated with living with severe asthma
- Discuss the role of biomarkers in guiding biologic treatment selection for patients with severe T2 asthma
- Recall evidence-based guidance on the long-term management of patients with severe T2 asthma
Foreword touchREVIEWS in Respiratory & Pulmonary Diseases Volume 6, Issue 1, 2021
Welcome to the latest issue of touchREVIEWS in Respiratory & Pulmonary Diseases. The past three years have been intensely busy, chaotic and traumatic, especially for those of us working in the respiratory field. Having personally spent hundreds of hours only working in COVID-19-related critical care, I have missed out on many new developments in respiratory healthcare. […]
Unravelling endotypes for treatment selection in severe type 2 asthma
Experts discuss how endotyping and biomarkers can help to guide optimal treatment selection in patients severe type 2 asthma
- Recall key data on the serious consequences of severe type 2 asthma
- Summarize severe asthma endotypes and the corresponding selection of biological therapies
- Evaluate the most recent evidence on key aspects of long-term management of patients with severe type 2 asthma
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!